<DOC>
	<DOCNO>NCT00117052</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy cinacalcet co-administered first meal dialysis comparable ( non-inferior ) efficacy cinacalcet administer dialysis study visit .</brief_summary>
	<brief_title>SENSOR : Study Investigate Cinacalcet Treatment Haemodialysis Patients With Secondary Hyperparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>CKD patient require dialysis ( HD , HDF , HF ) least 1 month enrolment An iPTH determination within 14 day randomisation must great equal 300 pg/mL ( biPTH great equal 150 pg/mL ) A serum calcium determination ( corrected calcium ) within 14 day randomisation must great equal 8.4 mg/dL [ 2.1 mmol/L ] Have unstable medical condition , define hospitalise , dialysis vascular access revision , within 30 day day 1 , otherwise unstable judgment investigator Are currently breastfeed Are perform peritoneal dialysis Have parathyroidectomy 3 month day 1 Have gastrointestinal disorder may associate impaired absorption orally administer medication inability swallow tablet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Clinical trial</keyword>
	<keyword>Amgen</keyword>
	<keyword>Secondary HyperParaThyroidism ( SHPT )</keyword>
	<keyword>Dialysis</keyword>
	<keyword>End Stage Renal Disease ( ESRD )</keyword>
	<keyword>KDOQI</keyword>
	<keyword>Cinacalcet</keyword>
</DOC>